Abcellera Biologics Inc ABCL

$13.14 -0.50 (-3.67%)

Valuation

Market cap
3,872,497,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
1,694,705
Avg volume
4,970,042
Day's range
$13.06 – $13.86
Shares out
306,611,000
Stochastic %K
100%
Beta
1.32
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

erpy Oct 29, 5:04 PM
$ABCL Last buy today ty shorty
0 replies
Stocktradesmoon Oct 29, 4:54 PM
$ABCL Ai doesn't know shit until $ABCL tells it what it knows. Of course Carl is a genius and his ahead of the curve. This is why he chose to keep his data off the LLM's and use proprietary in house built artificial intelligence and data integration software platforms. IP is safe!
0 replies
bullishtiger17 Oct 29, 4:37 PM
$ABSI $ABCL $IOVA tough day for IOVA, but still the trifecta of bios
0 replies
Stocktradesmoon Oct 29, 4:32 PM
$ABCL Astellas won Veozah approval in 2023, Bayer got Lynkuet in 2025: two pills proving demand for a non-hormonal hot flash fix. ABCL635 enters that market as one 600 mg shot, cutting flash frequency 83 percent against 33 percent on placebo.
0 replies
erpy Oct 29, 4:29 PM
$ABCL Yes sir we are locked and loaded for coming take off.
0 replies
Stocktradesmoon Oct 29, 4:25 PM
$ABCL Biotech leading before the theme confirms is actually the more honest signal... stocks move first, narratives catch up later.
0 replies
erpy Oct 29, 3:59 PM
$ABCL Grabbed another 1k ty. Lfg!!
0 replies
erpy Oct 29, 3:41 PM
$ABCL I added like how this is trading. Very strong 💪💪👍
1 replies